Background The natural history of follicular lymphoma is believed not to have changed over
the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Follicular lymphoma constitutes the most frequent indolent lymphoma, well characterized by
its clinical presentation related to nodal involvement and its morphologic and biologic …

Purpose Advanced-stage follicular lymphoma is considered incurable. The pace of
improvements in treatment has been slow. This article analyzes five sequential cohorts of …

Purpose Advanced follicular lymphomas (FL) are considered incurable with conventional
chemotherapy and there is no consensus on the best treatment approach. Southwest …

Purpose Despite several new treatment options, single-and multi-institution analyses have
not clarified whether survival patterns in follicular lymphoma (FL) patients have changed in …

Follicular lymphomas are characterized by relatively long median survivals and a
continuous pattern of relapse. The heterogeneity in these diseases is increasingly …

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large
prospective cohort study to identify current demographics and patterns of care of FL in the …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …